Loading data for NPPNY — first visit, this takes a few seconds.
Nippon Shinyaku Co., Ltd. (NPPNY): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | — | n/a | n/a |
| EPS | — | n/a | n/a |
Métricas
- Precio de compra
- 5.03
- Ingresos (TTM)
- 180B
- Beneficio neto (TTM)
- 31.6B
- n/a
- 0.72
- 7.99
- n/a
- P/B (TTM)
- 0.83
- P/S (TTM)
- 0.01
- Fecha de resultados
- n/a
- Precio de venta
- 5.98
- Volumen
- 175
- Volumen medio (20D)
- 73
- Abierto
- 5.75
- Anterior Cerrar
- 5.75
- Rango del día
- 5.75 - 5.75
- Rango de 52 semanas
- 5.03 - 15.21
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- $0.20 (3.40%)
- Fecha ex dividendo
- Mar 31, 2026
Acerca de Nippon Shinyaku Co., Ltd.
Ver perfil →Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Atthena Therapeutics, Inc. to develop ATSN-101 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and Regenex Bio Inc. to develop RGX-121 and RGX-111 for the treatment of mucopolysaccharidosis type I and II. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Atthena Therapeutics, Inc. to develop ATSN-101 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and Regenex Bio Inc. to develop RGX-121 and RGX-111 for the treatment of mucopolysaccharidosis type I and II. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Industria Drug Manufacturers - Specialty & Generic
Sector Healthcare
IPO Fecha Nov 16, 2016
Empleados 2,309
Bolsa de Valores OTC Markets OTCPK
Símbolo bursátil NPPNY
Sitio web https://www.nippon-shinyaku.co.jp